LACTB and infection: Regarding severe ESBL-E infections, a retrospective, multicenter study conducted in 2019 [11], including about 100 patients in ICU, found no significant difference between a beta-lactam–beta-lactamase inhibitor (βL–βLI) combination and carbapenem regarding Day-30 mortality but only 6% of these infections were urinary tract ones.